"I view SNY as an attractive, buyable dividend growth stock given Dupixent's ~€15B sales and 25% y/y growth, a 5.4% starting yield with a 10-year dividend CAGR ~12%, a 64% payout ratio, and an 11.9x P/E that looks materially cheap versus peers despite the early-2030s Dupixent patent cliff."
@ ~$47.73→ $61.206mo
"This High-Yield Pharma Stock Looks Like a Bargain Right Now"